Workflow
龙津退: 简式权益变动报告书(杨芳)

Core Viewpoint - The report details the equity change of Kunming Longjin Pharmaceutical Co., Ltd., indicating that the information discloser, Yang Fang, has increased her shareholding in the company, now holding over 5% of the total issued shares [1][4]. Group 1: Equity Change Details - The information discloser, Yang Fang, increased her shareholding from 18,874,000 shares (4.71%) to 21,310,300 shares (5.32%) [4]. - The increase in shares amounted to 2,436,300 shares, representing a change of 0.61% of the total issued shares [4]. - The acquisition occurred through a competitive bidding process on the stock exchange from June 24, 2025, to June 25, 2025 [4]. Group 2: Purpose and Future Plans - The purpose of this equity change is stated as personal investment [3]. - Yang Fang does not rule out the possibility of further increasing or decreasing her shareholding in the next 12 months [3]. Group 3: Shareholding Status - Yang Fang is not classified as a controlling shareholder or actual controller of the company, and this equity change will not affect the control of the company [4]. - There are no restrictions such as pledges or freezes on the shares held by Yang Fang [4].